Stock Track | Disc Medicine Soars 5% on Bullish Analyst Views and ASH Conference Updates

Stock Track

Nov 05, 2024

Shares of Disc Medicine (NASDAQ: IRON) surged 5.06% on Monday, November 5th, 2024, as the biopharmaceutical company gained traction from bullish analyst actions and its upcoming presentations at a major medical conference.

Leading the charge were Scotiabank and Morgan Stanley, which issued favorable reviews on Disc Medicine's prospects. Scotiabank reaffirmed its Buy rating on IRON stock and raised its price target to $70 from $62, citing the company's promising pipeline of potential treatments for serious hematologic diseases. Meanwhile, Morgan Stanley upgraded IRON to Overweight from Equalweight, assigning a price target of $85.

Additionally, Disc Medicine announced that it will present data from multiple programs in its hematology portfolio at the upcoming American Society of Hematology (ASH) Annual Meeting, scheduled for December 7-10, 2024, in San Diego. The company plans to provide clinical updates on its core development programs in erythropoietic protoporphyria (EPP), myelofibrosis (MF), and polycythemia vera, as well as share preclinical data supporting the potential use of its treatments in additional indications.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1162639444"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162639444\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162639444?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 23:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162639444","market":"us","top_or_hot":-1,"title":"Stock Track | Disc Medicine Soars 5% on Bullish Analyst Views and ASH Conference Updates","media":"Stock Track","content":"<p>Shares of Disc Medicine (NASDAQ: IRON) surged 5.06% on Monday, November 5th, 2024, as the biopharmaceutical company gained traction from bullish analyst actions and its upcoming presentations at a major medical conference.\n\n<p>Leading the charge were Scotiabank and Morgan Stanley, which issued favorable reviews on Disc Medicine's prospects. Scotiabank reaffirmed its Buy rating on IRON stock and raised its price target to $70 from $62, citing the company's promising pipeline of potential treatments for serious hematologic diseases. Meanwhile, Morgan Stanley upgraded IRON to Overweight from Equalweight, assigning a price target of $85.\n\n<p>Additionally, Disc Medicine announced that it will present data from multiple programs in its hematology portfolio at the upcoming American Society of Hematology (ASH) Annual Meeting, scheduled for December 7-10, 2024, in San Diego. The company plans to provide clinical updates on its core development programs in erythropoietic protoporphyria (EPP), myelofibrosis (MF), and polycythemia vera, as well as share preclinical data supporting the potential use of its treatments in additional indications.","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Disc Medicine Soars 5% on Bullish Analyst Views and ASH Conference Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Disc Medicine Soars 5% on Bullish Analyst Views and ASH Conference Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-05 23:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Disc Medicine (NASDAQ: IRON) surged 5.06% on Monday, November 5th, 2024, as the biopharmaceutical company gained traction from bullish analyst actions and its upcoming presentations at a major medical conference.\n\n<p>Leading the charge were Scotiabank and Morgan Stanley, which issued favorable reviews on Disc Medicine's prospects. Scotiabank reaffirmed its Buy rating on IRON stock and raised its price target to $70 from $62, citing the company's promising pipeline of potential treatments for serious hematologic diseases. Meanwhile, Morgan Stanley upgraded IRON to Overweight from Equalweight, assigning a price target of $85.\n\n<p>Additionally, Disc Medicine announced that it will present data from multiple programs in its hematology portfolio at the upcoming American Society of Hematology (ASH) Annual Meeting, scheduled for December 7-10, 2024, in San Diego. The company plans to provide clinical updates on its core development programs in erythropoietic protoporphyria (EPP), myelofibrosis (MF), and polycythemia vera, as well as share preclinical data supporting the potential use of its treatments in additional indications.\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRON","symbol_name":"Disc Medicine","start_time":0,"source_url":"","article_id":"1162639444","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162639444","pubTimestamp":1730822299,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Disc Medicine  surged 5.06% on Monday, November 5th, 2024, as the biopharmaceutical company gained traction from bullish analyst actions and its upcoming presentations at a major medical conference.Leading the charge were Scotiabank and Morgan Stanley, which issued favorable reviews on Disc Medicine's prospects. Scotiabank reaffirmed its Buy rating on IRON stock and raised its price target to $70 from $62, citing the company's promising pipeline of potential treatments for serious hema","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRON":"Disc Medicine"},"translate_title":"股票赛道Disc Medicine因看涨分析师观点和ASH会议更新而飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRON":1},"content_text":"Shares of Disc Medicine (NASDAQ: IRON) surged 5.06% on Monday, November 5th, 2024, as the biopharmaceutical company gained traction from bullish analyst actions and its upcoming presentations at a major medical conference.\n\nLeading the charge were Scotiabank and Morgan Stanley, which issued favorable reviews on Disc Medicine's prospects. Scotiabank reaffirmed its Buy rating on IRON stock and raised its price target to $70 from $62, citing the company's promising pipeline of potential treatments for serious hematologic diseases. Meanwhile, Morgan Stanley upgraded IRON to Overweight from Equalweight, assigning a price target of $85.\n\nAdditionally, Disc Medicine announced that it will present data from multiple programs in its hematology portfolio at the upcoming American Society of Hematology (ASH) Annual Meeting, scheduled for December 7-10, 2024, in San Diego. The company plans to provide clinical updates on its core development programs in erythropoietic protoporphyria (EPP), myelofibrosis (MF), and polycythemia vera, as well as share preclinical data supporting the potential use of its treatments in additional indications.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}